Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates

Parasites & Vectors

Table 1 Prevalence of Plasmodium vivax infection and oocyst numbers in mosquitoes fed on antisera

P. vivax clinical samples	Group	Oocyst density, median (IQR)	Mean oocyst density (oocysts/midgut)	% inhibition of oocyst density^a	P-value^b	Infected/dssected^c	Infection rate (%)	% inhibition of prevalance^d	P-value^e
#1	Control	8.0 (3.3–9.0)	6.8			20/20	100
	PvPH	8.0 (6.0–9.0)	8.1	− 19.1	0.933	20/20	100	-
	PvSOP26	6.0 (4.0–8.0)	6.7	0.7	1.000	20/20	100	-	1.000
#2	Control	88.5 (69.8–132.5)	94.4			19/20	95
	PvPH	78.0 (56.8–127.8)	85.2	9.8	1.000	19/20	95	-
	PvSOP26	4.5 (2.0–12.5)	7.5	92.0	0.0001***	17/20	85	10	1.000
#3	Control	66.5 (59.0–80.0)	67.8			20/20	100
	PvPH	67.5 (49.8–86.8)	66.7	1.6	1.000	20/20	100	-
	PvSOP26	11.5 (1.0–19.8)	10.80	84.1	0.014*	16/20	80	20	0.106

IQR Inter-quartile range
*P < 0.05, ***P < 0.001
^aPercentage inhibition of oocyst density was calculated as (mean_control − mean_{PvPH/PvPSOP26})/mean_control × 100%
^bMean number of oocysts was statistically analyzed (Mann–Whitney U-test) and P-values of < 0.05 were considered to be statistically significant. #2 control vs. PvSOP26: U₍₁₉₎ = 40.5, Z = − 4.32, P < 0.0001; #3 control vs PvSOP26: U₍₁₉₎ = 13, Z = − 5.06, P = 0.014
^cInfection prevalence was calculated by number of oocyst-infected mosquitoes per 20 mosquitoes dissected in each group (Infected/dissected)
^d% inhibition of prevalence was calculated as % prevalence_control − % prevalence_{PvPH/PvPSOP26}
^ePrevalance was statistically analyzed by Fisher’s exact test. P-values < 0.05 were considered to be statistically significant

ISSN: 1756-3305